Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broncho-Vaxom for Prevention of COPD Exacerbations
2025-524501-32-02Phase 4Authorised
- Sponsor
- Semmelweis University, University Of Pecs
- Start
- Mar 2026
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Broncho-Vaxom + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Reduction in number of moderate and severe COPD exacerbations at 12 months. Planned start Mar 2026; status: authorised.
02
Drugs
OM-85
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-524501-32-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524501-32-02.